alexa In Vivo Electroporation For Improvement Of Therapeutic DNA Vaccine Against Chronic Hepatitis B Infection
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Lucyna Cova
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
D espite the existence of an effective prophylactic vaccine, chronic hepatitis B virus (HBV) infection remains a major public health problem. DNA-based vaccination has emerged as promising immunotherapeutic approach against chronic hepatitis B, although its efficacy needs to be increased as indicated by the results of first clinical trials. In this regard in vivo electroporation (EP)-mediated delivery appears of particular interest to improve therapeutic potency of DNA vaccines against chronic viral diseases. However, little was known of the ability of EP to improve DNA vaccine for therapy of chronic hepatitis B infection. We explored EP-mediated DNA vaccine delivery for hepatitis B immunotherapy using the duck HBV (DHBV) infection model, which is a reference for novel anti-HBV approaches evaluation. We first demonstrated in na?ve animals that EP was able to dramatically enhance neutralizing potency of DNA vaccine leading to highly neutralizing, multi-specific B-cell response at clinically feasible DNA dose. Next, the therapeutic benefit of EP-mediated DNA vaccine delivery was investigated. The therapy of chronic DHBV-carrier ducks with EP-delivered DNA vaccine encoding viral proteins (envelope, core) and IFN- γ resulted in a marked and sustained decrease in viremia titers as compared with standard needle DNA injection. Importantly, a significant decrease in intrahepatic covalently closed circular viral DNA (cccDNA) form, responsible for chronicity of infection, was observed following EP of DNA vaccine. In addition a break of immune-tolerance was observed after DNA vaccine administration by EP. Collectively, our data indicate that electroporation is able to dramatically enhance therapeutic potency of DNA vaccine targeting hepadnaviral proteins supporting clinical application of this approach against chronic hepatitis B.
Lucyna Cova obtained her PhD in Biochemistry at the University Claude Bernard in Lyon, France. She held a Post-doctorate position at the Wistar Institute in Philadelphia. Thereafter she joined Institut National de la Sante et Recherche Medicale (INSERM), which is a French medical research institute (equivalent of NIH). Currently she is a research Director at INSERM and a co-leader of a team working on Novel approaches against Hepatitis B and C infections at Cancer Research Center of Lyon. She has expertise in viral hepatitis. Over the past decade her research focused on the development of therapeutic DNA vaccines against chronic hepatitis B.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version